ROLE OF GENETIC MODIFIERS IN BLEEDING DISORDERS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 血小板膜上整合素α 2 β 1和糖蛋白Ib-1X-V复合物表达的差异影响血管性血友病和其他由血小板粘附于内皮下受损引起的出血性疾病的临床表现。 在过去的4年中，通过GCRC的先前方案#0214，招募了数百名患有血管性血友病的个体及其亲属。 本研究的主要目标是完成无关对照的招募。 病例/对照研究将代表相关性研究的金标准，无相关对照的可用性对其完成至关重要。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Differences in expression of the integrin alpha2 beta1 and glycoprotein lb-1X-V complex on the platelet membrane influence the clinical presentation of von Willebrand disease and other bleeding disorders caused by impaired platelet adhesion to the subendothelium. Over the last 4 years several hundred individuals with von Willebrand disease have been recruited as well as their relatives through a previous protocol in the GCRC, #0214. The main goal of this study is to complete the recruitment of unrelated controls. Case/control studies will represent the gold standard of association studies and the availability of unrelated controls is essential for their completion.